Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.

Vuokko NummiAnna-Elina LehtinenAlfonso Iorio Timea Szanto Riitta Lassila

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2022)

Our cohort study confirms the successful experience of switching to EHL FVIII products, with decreased infusion frequency, factor consumption and excellent clinical efficacy.

Keyphrases